RV299

DRUG2 trials

Sponsors

Pfizer

Conditions

Respiratory Syncytial Virus (RSV)Respiratory Syncytial Virus Infections

Phase 1

Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults

CompletedNCT06033612

PfizerRespiratory Syncytial Virus Infections

Start: 2021-11-12End: 2022-07-27Updated: 2023-09-13

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

CompletedNCT06067191

PfizerRespiratory Syncytial Virus (RSV)

Start: 2022-08-08End: 2022-12-02Updated: 2024-10-21